NasdaqCM:SLSBiotechs
SELLAS Life Sciences (SLS) Is Up 21.8% After REGAL Trial Clears Key Continuation Review - What's Changed
In recent months, SELLAS Life Sciences Group reported encouraging activity for SLS009 in combination with AZA/VEN in relapsed/refractory AML and confirmed that the Independent Data Monitoring Committee recommended the Phase 3 REGAL trial continue without modification, with final analysis expected before year-end.
This combination of positive efficacy signals and trial continuity strengthens the clinical credibility of SELLAS’s pipeline in a difficult-to-treat leukemia setting.
We’ll now...